• China’s NMPA drug review center cleared InnoCare’s registrational Phase 3 trial of mesutoclax with azacitidine in treatment-naive AML.
• Study pits mesutoclax regimen against venetoclax with azacitidine in elderly or unfit patients; primary endpoint is overall survival.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608172149PRIMZONEFULLFEED9811780) on August 18, 2026, and is solely responsible for the information contained therein.